<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5766">
  <stage>Registered</stage>
  <submitdate>24/12/2015</submitdate>
  <approvaldate>24/12/2015</approvaldate>
  <nctid>NCT02642159</nctid>
  <trial_identification>
    <studytitle>Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)</studytitle>
    <scientifictitle>A Randomized, Open-Label, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab Versus Usual Care in Patients With Type 2 Diabetes and Mixed Dyslipidemia at High Cardiovascular Risk With Non-HDL-C Not Adequately Controlled With Maximally Tolerated Statin Therapy</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2015-001934-19</secondaryid>
    <secondaryid>LPS14354</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Dyslipidemia</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Other cardiovascular diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Blood </conditioncode1>
      <conditioncode2>Other blood disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - ALIROCUMAB SAR236553 (REGN727)
Treatment: drugs - placebo
Treatment: drugs - statins
Treatment: drugs - ezetimibe
Treatment: drugs - fenofibrate
Treatment: drugs - nicotinic acid
Treatment: drugs - omega-3 fatty acids

Experimental: Alirocumab - Will be injected subcutaneously every 2 weeks starting with Dose 1 with potential blinded uptitration to Dose 2 at Week 12. Background therapy such as antihyperglycemic agents and statins will be administered as applicable or as per Investigator's judgment. A placebo injection for training purposes will be administered to the patients.

Active Comparator: Usual Care - Will be administered orally based on the selection of the Investigator prior to randomization and includes initiation of either ezetimibe, fenofibrate, nicotinic acid or omega-3 fatty acids. Alternatively, if randomized to the usual care arm, the Investigator may select the addition of no additional lipid lowering agent. Background therapy such as antihyperglycemic agents and statins will be administered as applicable or as per Investigator's judgment. A placebo injection for training purposes will be administered to the patients.


Treatment: drugs: ALIROCUMAB SAR236553 (REGN727)
Pharmaceutical form:solution for injection Route of administration: subcutaneous

Treatment: drugs: placebo
Pharmaceutical form:solution for injection Route of administration: subcutaneous

Treatment: drugs: statins
Pharmaceutical form:tablet Route of administration: oral

Treatment: drugs: ezetimibe
Pharmaceutical form:tablet Route of administration: oral

Treatment: drugs: fenofibrate
Pharmaceutical form:tablet Route of administration: oral

Treatment: drugs: nicotinic acid
Pharmaceutical form:tablet Route of administration: oral

Treatment: drugs: omega-3 fatty acids
Pharmaceutical form:tablet Route of administration: oral

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Percent change in non-HDL-C in the intent-to-treat (ITT) population</outcome>
      <timepoint>From baseline to Week 24</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Percent change in measured LDL-C</outcome>
      <timepoint>From baseline to Week 24</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percent change in non-HDL-C</outcome>
      <timepoint>From baseline to Week 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percent change in measured LDL-C</outcome>
      <timepoint>From baseline to Week 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percent change in Apo B</outcome>
      <timepoint>From baseline to Week 24</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percent change in Total-C</outcome>
      <timepoint>From baseline to Week 24</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percent change in Lp(a)</outcome>
      <timepoint>From baseline to Week 24</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percent change in TG</outcome>
      <timepoint>From baseline to Week 24</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percent change in HDL-C</outcome>
      <timepoint>From baseline to Week 24</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percent change in LDL-C particle number</outcome>
      <timepoint>From baseline to Week 24</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Number of patients with adverse events</outcome>
      <timepoint>From baseline to Week 32</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Inclusion criteria:

          -  Patients with type 2 diabetes and mixed dyslipidemia whose non-high-density
             lipoprotein cholesterol (non-HDL-C) is not adequately controlled with a stable,
             maximum dose/regimen of statin that is tolerated by the patient.

          -  18 years of age or more.

          -  Documented history of atherosclerotic cardiovascular disease (ASCVD) or at least one
             additional cardiovascular risk factor.

          -  Non-HDL-C of 100 mg/dL or greater.

          -  Triglycerides greater than or equal to 150 mg/dL and less than 500 mg/dL.

          -  Stable anti-hyperglycemic agents for at least 3 months.

          -  No change in weight of more than 5 kg within the prior 3 months.

          -  On stable dose of medications that are known to influence weight and/or lipids within
             the last 3 months.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Exclusion criteria:

          -  Use of any lipid modifying therapies other than statins within the last 4 weeks (eg,
             ezetimibe, fenofibrate, nicotinic acid, omega-3 fatty acids, etc.) or use of over the
             counter products/nutraceuticals known to impact lipids (eg, red yeast rice) within the
             last 4 weeks.

          -  Currently drinking more than 2 standard alcoholic drinks per day.

          -  Body Mass Index (BMI) &gt;45 kg/mÂ² or currently enrolled in a weight loss program and
             still in active phase of weight loss.

          -  Glycosylated hemoglobin (HbA1c) 9% or greater.

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate />
    <actualstartdate>15/03/2016</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>413</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>18/05/2017</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Investigational Site Number 036102 - Herston</hospital>
    <hospital>Investigational Site Number 036104 - Merewether</hospital>
    <hospital>Investigational Site Number 036101 - St Leonards</hospital>
    <postcode>4006 - Herston</postcode>
    <postcode>2291 - Merewether</postcode>
    <postcode>2065 - St Leonards</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arkansas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Idaho</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kentucky</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Louisiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maryland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Nebraska</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Nevada</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Dakota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oregon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>South Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Utah</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Virginia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Campinas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Fortaleza</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Sao Paulo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>SÃ£o paulo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>SÃ£o Paulo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>SÃ£O Paulo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Finland</country>
      <state>Oulu</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Finland</country>
      <state>Tampere</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Dippoldiswalde</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Dresden</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Essen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Goch</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Karlsruhe</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>KÃ¼nzing</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Oldenburg in Holstein</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Pirna</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Beer Sheva</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Petach Tikva</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Petach tikva</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Rehovot</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Tel-Aviv</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Bergamo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Catanzaro</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Napoli</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Padova</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Partinico</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Pisa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Roma</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Torino</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Kuwait</country>
      <state>Kuwait</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Lebanon</country>
      <state>Beirut</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Lebanon</country>
      <state>Hazmieh</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Norway</country>
      <state>Oslo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>GÃ¶teborg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Stockholm</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>GenÃ¨ve</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Olten</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Reinach</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Adana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Ankara</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Corum</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Hatay</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Izmir</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Kayseri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Samsun</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Arab Emirates</country>
      <state>Dubai</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Exeter</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Manchester</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Middlesborough</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Stevenage</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Torquay</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>West Bromwich</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Sanofi</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>Regeneron Pharmaceuticals</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Primary Objective:

      To demonstrate the superiority of alirocumab in comparison with usual care in the reduction
      of non-high-density lipoprotein cholesterol (non-HDL-C) in patients with type 2 diabetes and
      mixed dyslipidemia at high cardiovascular risk with non-HDL-C not adequately controlled with
      maximally tolerated statin therapy.

      Secondary Objectives:

        -  To demonstrate whether alirocumab is superior in comparison with usual care in its
           effects on other lipid parameters (ie, low-density lipoprotein cholesterol (LDL-C),
           apolipoprotein B (Apo B), total cholesterol (Total -C), lipoprotein a (Lp[a]),
           high-density lipoprotein cholesterol (HDL-C), triglycerides (TGs), triglyceride rich
           lipoproteins (TGRLs), apolipoprotein A-1 (Apo A-1), apolipoprotein C-III (Apo C-III),
           lipid subfractions by nuclear magnetic resonance (NMR) spectroscopy (ie, LDL-C particle
           size and LDL, very low-density lipoprotein [VLDL], HDL, and intermediate-density
           lipoprotein [IDL] particle number).

        -  To assess changes in diabetes parameters with alirocumab vs. usual care treatment.

        -  To demonstrate the safety and tolerability of alirocumab.

        -  To evaluate treatment acceptance of alirocumab.

        -  To evaluate PCSK9 concentrations and antibody development.

        -  To demonstrate the superiority of alirocumab vs. fenofibrate on non-HDL-C and other
           lipid parameters (subgroup analysis).</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02642159</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Clinical Sciences &amp; Operations</name>
      <address>Sanofi</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>